Are you over 18 and want to see adult content?
More Annotations
A complete backup of make-and-build-dog-stuff.com
Are you over 18 and want to see adult content?
A complete backup of clutchbrakeforum.com
Are you over 18 and want to see adult content?
A complete backup of mysecretwoods.com
Are you over 18 and want to see adult content?
A complete backup of stiintasitehnica.com
Are you over 18 and want to see adult content?
A complete backup of cysticfibrosis.ca
Are you over 18 and want to see adult content?
A complete backup of wp-themespoint.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of www.blackmonsterterror.com
Are you over 18 and want to see adult content?
A complete backup of www.www.quartier-rouge.be
Are you over 18 and want to see adult content?
A complete backup of celebfanforum.com
Are you over 18 and want to see adult content?
A complete backup of perfectgirls.net
Are you over 18 and want to see adult content?
A complete backup of www.kaufmich.com
Are you over 18 and want to see adult content?
A complete backup of www.redlights.be
Are you over 18 and want to see adult content?
A complete backup of www.naturistscans.com
Are you over 18 and want to see adult content?
Text
affordability.
CONTACT US | LAURUS LABS 400 Connell Drive, Suite 5200 Berkeley Heights, NJ 07922. Tel: 313-580-0229. Email: tversosky@lauruslabs.com. Laurus Generics GmbH Inc. Van-der-Smissen-Strasse 1, 22767 Hamburg, Germany. Tel: +49 40 3808 47 64.
INVESTORS | LAURUS LABS For redressal of any grievances, the shareholders/investors may contact the following: The Company Secretary. Laurus Labs Limited. 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 500 034, India. Phone: +91 40 39804333. E-mail: Secretarial@Lauruslabs.com. SYNTHESIS | LAURUS LABS We offer cutting-edge synthesis services trusted by leading research labs and companies worldwide. Innovative, robust and scalable chemistry is the core strength of Laurus. We support drug development and manufacturing programs for global pharmaceutical and biotech companies at all stages from pre-clinical stage to commercialization. FACILITIES | LAURUS LABS Plot No. 21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India. API manufacturing facility includes capacity for ingredients, synthesis and contract manufacturing. Spread across 34 acres, and 1000+ employees; Isolated FINANCIALS | LAURUS LABS FY 2017-18. Sriam Labs Pvt Ltd-Audited Financials. Laurus Synthesis Inc Audited Financials INR. Laurus Synthesis Inc Audited Financials USD. Laurus Holdings Ltd Audited Financials INR. Laurus Holdings Ltd Audited Financials GBP. Laurus Generics Inc-Audited Financials. Laurus Generics GmbH-Audited Financials. FY 2016-17. CAREERS | LAURUS LABS CAREERS We are a team of thinkers and doers who share a passion to make a positive difference. Ask anyone of their impression of Laurus Labs. They will tell you that it feels like a close-knit family and that captures the essence of the Laurus experience.INGREDIENTS
We developed technologies for several key ingredients including carotenoids (Betacarotene, Astaxanthin), Huperzine A and novel nutraceutical co-crystals of Pterostilbene, Caffeine and Curcumin with enhanced bioavailability and controlled absorption properties. Laurus also manufactures safe and effective natural ingredients for weightmanagement
LAURUS LABS
Key Indices' highlighting the progress of Laurus 55+ 290+ R&D Labs Manufacturing Facilities (India, USA) revenue in FY17 8 (8 API (incl.Pilot); 1 FDF)
LAURUS LABSABOUT USBUSINESS UNITSINVESTORSMEDIACAREERSCONTACT US Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences". Oct 29, 2020. Laurus Labs Press Release Board Meeting Oct 29 2020. Oct 29, 2020. Q2 H1 FY21 Press Release Oct 29 2020. Jul 30, 2020. Press Release - Strong Revenue growth of 77% and PAT growth of 1047%. ABOUT US | LAURUS LABS Home / About us As a leading research-driven pharmaceutical company, Laurus Labs aims to improve the quality of life for millions around the world. We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality andaffordability.
CONTACT US | LAURUS LABS 400 Connell Drive, Suite 5200 Berkeley Heights, NJ 07922. Tel: 313-580-0229. Email: tversosky@lauruslabs.com. Laurus Generics GmbH Inc. Van-der-Smissen-Strasse 1, 22767 Hamburg, Germany. Tel: +49 40 3808 47 64.
INVESTORS | LAURUS LABS For redressal of any grievances, the shareholders/investors may contact the following: The Company Secretary. Laurus Labs Limited. 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 500 034, India. Phone: +91 40 39804333. E-mail: Secretarial@Lauruslabs.com. SYNTHESIS | LAURUS LABS We offer cutting-edge synthesis services trusted by leading research labs and companies worldwide. Innovative, robust and scalable chemistry is the core strength of Laurus. We support drug development and manufacturing programs for global pharmaceutical and biotech companies at all stages from pre-clinical stage to commercialization. FACILITIES | LAURUS LABS Plot No. 21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India. API manufacturing facility includes capacity for ingredients, synthesis and contract manufacturing. Spread across 34 acres, and 1000+ employees; Isolated FINANCIALS | LAURUS LABS FY 2017-18. Sriam Labs Pvt Ltd-Audited Financials. Laurus Synthesis Inc Audited Financials INR. Laurus Synthesis Inc Audited Financials USD. Laurus Holdings Ltd Audited Financials INR. Laurus Holdings Ltd Audited Financials GBP. Laurus Generics Inc-Audited Financials. Laurus Generics GmbH-Audited Financials. FY 2016-17. CAREERS | LAURUS LABS CAREERS We are a team of thinkers and doers who share a passion to make a positive difference. Ask anyone of their impression of Laurus Labs. They will tell you that it feels like a close-knit family and that captures the essence of the Laurus experience.INGREDIENTS
We developed technologies for several key ingredients including carotenoids (Betacarotene, Astaxanthin), Huperzine A and novel nutraceutical co-crystals of Pterostilbene, Caffeine and Curcumin with enhanced bioavailability and controlled absorption properties. Laurus also manufactures safe and effective natural ingredients for weightmanagement
LAURUS LABS
Key Indices' highlighting the progress of Laurus 55+ 290+ R&D Labs Manufacturing Facilities (India, USA) revenue in FY17 8 (8 API (incl.Pilot); 1 FDF)
WHAT WE DO | LAURUS LABS Home / What we do At Laurus Labs, we are driven by an ambitious vision to secure market leadership in our core focus areas. Laurus Labs aspires to become a most-admired pharmaceutical company with a clear focus on four growing areas: APIs, FDFs, ingredients and synthesis.INGREDIENTS
We developed technologies for several key ingredients including carotenoids (Betacarotene, Astaxanthin), Huperzine A and novel nutraceutical co-crystals of Pterostilbene, Caffeine and Curcumin with enhanced bioavailability and controlled absorption properties. Laurus also manufactures safe and effective natural ingredients for weightmanagement
MEDIA | LAURUS LABS
Media Coverage. 29 Apr 2021. Laurus Labs Financial Results Q4 FY 2021 Press Release. 04 Mar 2021. Laurus labs promoters, Dr.Satyanarayana chava, founder and ceo & Mrs. Nagarani chava, promoter, are set to release the pledge of shares of the company. 10 Feb 2021. Laurus Labs wins coveted Golden Peacock Award for Excellence in CorporateGovernance.
SHAREHOLDING
Shares. Unclaimed dividend details of 2019-20 Interim Dividend (Sep 30, 2020) Unclaimed Dividend Details of 2018-19 (October 31, 2019) Unclaimed Dividend Details of 2017-18 (October 31, 2018) Unclaimed Dividend Details of 2016-17 (November 28, 2017) Shareholding RESEARCH & DEVELOPMENT As a science-led pharmaceutical company, we invest in cutting-edge research to develop new cures for challenging diseases. We are focused on undertaking dedicated R&D in areas with significant demand. Our research team of over 750 scientists constitutes a quarter of our total workforce. Our systematic approach to the selection of molecules STRENGTHS & STRATEGY Established track record of delivering growth. From our incorporation in 2005, we have delivered consistent growth both in terms of financial and operational metrics. Our total revenues have grown at a CAGR of 41.1% from FY 2012 to FY 2016 and our restated profit has grown at a CAGR of 57.5% between FY 2012 and FY 2016.GENERICS FDF
Laurus has dedicated formulation research labs, laboratory-scale clinical supply facilities, and analytical research labs capable of developing different types of dosage forms. We create tangible value for customers by leveraging our cost-effective processes and large capacities in the API business. Our FDF business builds on ourstrengths in
GENERICS API
Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed a wide range of in-house APIs and intermediates. We focus on chemistry where we can make a difference and combine innovation with efficiency to develop cost-effective and hence affordable processes. We regularly invest inbuilding capacities
CORPORATE GOVERNANCE Laurus Labs is committed to conducting its business with the highest standards of integrity, with the Board providing indispensable leadership. The corporate governance framework at Laurus Labs is based on an effective independent Board, separation of the Board’s supervisory role from the executive management team, constitution ofthe Board
CORPORATE SUSTAINABILITY ABOUT US / Corporate Sustainability As a responsible corporate citizen, we will conduct our business with complete respect for the environment and community. We have adopted a Corporate Social Responsibility (“CSR”) policy in compliance with the requirements of the Companies Act, 2013 and the Companies (Corporate Social Responsibility) Rules, 2014 notified by Central Government. LAURUS LABSABOUT USBUSINESS UNITSINVESTORSMEDIACAREERSCONTACT US Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences". Oct 29, 2020. Laurus Labs Press Release Board Meeting Oct 29 2020. Oct 29, 2020. Q2 H1 FY21 Press Release Oct 29 2020. Jul 30, 2020. Press Release - Strong Revenue growth of 77% and PAT growth of 1047%. ABOUT US | LAURUS LABS Home / About us As a leading research-driven pharmaceutical company, Laurus Labs aims to improve the quality of life for millions around the world. We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality andaffordability.
CONTACT US | LAURUS LABS 400 Connell Drive, Suite 5200 Berkeley Heights, NJ 07922. Tel: 313-580-0229. Email: tversosky@lauruslabs.com. Laurus Generics GmbH Inc. Van-der-Smissen-Strasse 1, 22767 Hamburg, Germany. Tel: +49 40 3808 47 64.
INVESTORS | LAURUS LABS For redressal of any grievances, the shareholders/investors may contact the following: The Company Secretary. Laurus Labs Limited. 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 500 034, India. Phone: +91 40 39804333. E-mail: Secretarial@Lauruslabs.com. FACILITIES | LAURUS LABS Plot No. 21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India. API manufacturing facility includes capacity for ingredients, synthesis and contract manufacturing. Spread across 34 acres, and 1000+ employees; Isolated CAREERS | LAURUS LABS CAREERS We are a team of thinkers and doers who share a passion to make a positive difference. Ask anyone of their impression of Laurus Labs. They will tell you that it feels like a close-knit family and that captures the essence of the Laurus experience. SYNTHESIS | LAURUS LABS We offer cutting-edge synthesis services trusted by leading research labs and companies worldwide. Innovative, robust and scalable chemistry is the core strength of Laurus. We support drug development and manufacturing programs for global pharmaceutical and biotech companies at all stages from pre-clinical stage to commercialization.INGREDIENTS
We developed technologies for several key ingredients including carotenoids (Betacarotene, Astaxanthin), Huperzine A and novel nutraceutical co-crystals of Pterostilbene, Caffeine and Curcumin with enhanced bioavailability and controlled absorption properties. Laurus also manufactures safe and effective natural ingredients for weightmanagement
FINANCIALS | LAURUS LABS FY 2017-18. Sriam Labs Pvt Ltd-Audited Financials. Laurus Synthesis Inc Audited Financials INR. Laurus Synthesis Inc Audited Financials USD. Laurus Holdings Ltd Audited Financials INR. Laurus Holdings Ltd Audited Financials GBP. Laurus Generics Inc-Audited Financials. Laurus Generics GmbH-Audited Financials. FY 2016-17.LAURUS LABS
Key Indices' highlighting the progress of Laurus 55+ 290+ R&D Labs Manufacturing Facilities (India, USA) revenue in FY17 8 (8 API (incl.Pilot); 1 FDF)
LAURUS LABSABOUT USBUSINESS UNITSINVESTORSMEDIACAREERSCONTACT US Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences". Oct 29, 2020. Laurus Labs Press Release Board Meeting Oct 29 2020. Oct 29, 2020. Q2 H1 FY21 Press Release Oct 29 2020. Jul 30, 2020. Press Release - Strong Revenue growth of 77% and PAT growth of 1047%. ABOUT US | LAURUS LABS Home / About us As a leading research-driven pharmaceutical company, Laurus Labs aims to improve the quality of life for millions around the world. We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality andaffordability.
CONTACT US | LAURUS LABS 400 Connell Drive, Suite 5200 Berkeley Heights, NJ 07922. Tel: 313-580-0229. Email: tversosky@lauruslabs.com. Laurus Generics GmbH Inc. Van-der-Smissen-Strasse 1, 22767 Hamburg, Germany. Tel: +49 40 3808 47 64.
INVESTORS | LAURUS LABS For redressal of any grievances, the shareholders/investors may contact the following: The Company Secretary. Laurus Labs Limited. 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 500 034, India. Phone: +91 40 39804333. E-mail: Secretarial@Lauruslabs.com. FACILITIES | LAURUS LABS Plot No. 21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India. API manufacturing facility includes capacity for ingredients, synthesis and contract manufacturing. Spread across 34 acres, and 1000+ employees; Isolated SYNTHESIS | LAURUS LABS We offer cutting-edge synthesis services trusted by leading research labs and companies worldwide. Innovative, robust and scalable chemistry is the core strength of Laurus. We support drug development and manufacturing programs for global pharmaceutical and biotech companies at all stages from pre-clinical stage to commercialization. CAREERS | LAURUS LABS CAREERS We are a team of thinkers and doers who share a passion to make a positive difference. Ask anyone of their impression of Laurus Labs. They will tell you that it feels like a close-knit family and that captures the essence of the Laurus experience.INGREDIENTS
We developed technologies for several key ingredients including carotenoids (Betacarotene, Astaxanthin), Huperzine A and novel nutraceutical co-crystals of Pterostilbene, Caffeine and Curcumin with enhanced bioavailability and controlled absorption properties. Laurus also manufactures safe and effective natural ingredients for weightmanagement
FINANCIALS | LAURUS LABS FY 2017-18. Sriam Labs Pvt Ltd-Audited Financials. Laurus Synthesis Inc Audited Financials INR. Laurus Synthesis Inc Audited Financials USD. Laurus Holdings Ltd Audited Financials INR. Laurus Holdings Ltd Audited Financials GBP. Laurus Generics Inc-Audited Financials. Laurus Generics GmbH-Audited Financials. FY 2016-17.LAURUS LABS
Key Indices' highlighting the progress of Laurus 55+ 290+ R&D Labs Manufacturing Facilities (India, USA) revenue in FY17 8 (8 API (incl.Pilot); 1 FDF)
WHAT WE DO | LAURUS LABS Home / What we do At Laurus Labs, we are driven by an ambitious vision to secure market leadership in our core focus areas. Laurus Labs aspires to become a most-admired pharmaceutical company with a clear focus on four growing areas: APIs, FDFs, ingredients and synthesis.INGREDIENTS
We developed technologies for several key ingredients including carotenoids (Betacarotene, Astaxanthin), Huperzine A and novel nutraceutical co-crystals of Pterostilbene, Caffeine and Curcumin with enhanced bioavailability and controlled absorption properties. Laurus also manufactures safe and effective natural ingredients for weightmanagement
MEDIA | LAURUS LABS
Media Coverage. 29 Apr 2021. Laurus Labs Financial Results Q4 FY 2021 Press Release. 04 Mar 2021. Laurus labs promoters, Dr.Satyanarayana chava, founder and ceo & Mrs. Nagarani chava, promoter, are set to release the pledge of shares of the company. 10 Feb 2021. Laurus Labs wins coveted Golden Peacock Award for Excellence in CorporateGovernance.
RESEARCH & DEVELOPMENT As a science-led pharmaceutical company, we invest in cutting-edge research to develop new cures for challenging diseases. We are focused on undertaking dedicated R&D in areas with significant demand. Our research team of over 750 scientists constitutes a quarter of our total workforce. Our systematic approach to the selection of moleculesSHAREHOLDING
Shares. Unclaimed dividend details of 2019-20 Interim Dividend (Sep 30, 2020) Unclaimed Dividend Details of 2018-19 (October 31, 2019) Unclaimed Dividend Details of 2017-18 (October 31, 2018) Unclaimed Dividend Details of 2016-17 (November 28, 2017) Shareholding STRENGTHS & STRATEGY Established track record of delivering growth. From our incorporation in 2005, we have delivered consistent growth both in terms of financial and operational metrics. Our total revenues have grown at a CAGR of 41.1% from FY 2012 to FY 2016 and our restated profit has grown at a CAGR of 57.5% between FY 2012 and FY 2016.GENERICS FDF
Laurus has dedicated formulation research labs, laboratory-scale clinical supply facilities, and analytical research labs capable of developing different types of dosage forms. We create tangible value for customers by leveraging our cost-effective processes and large capacities in the API business. Our FDF business builds on ourstrengths in
GENERICS API
Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed a wide range of in-house APIs and intermediates. We focus on chemistry where we can make a difference and combine innovation with efficiency to develop cost-effective and hence affordable processes. We regularly invest inbuilding capacities
DISCLOSURES
04 Mar 2021. Laurus labs promoters, Dr.Satyanarayana chava, founder and ceo & Mrs. Nagarani chava, promoter, are set to release the pledge of shares of the company. 20 Feb 2021. Laurus Labs wins coveted Golden Peacock Award for Excellence in Corporate Governance. CORPORATE GOVERNANCE Laurus Labs is committed to conducting its business with the highest standards of integrity, with the Board providing indispensable leadership. The corporate governance framework at Laurus Labs is based on an effective independent Board, separation of the Board’s supervisory role from the executive management team, constitution ofthe Board
LAURUS LABSABOUT USBUSINESS UNITSINVESTORSMEDIACAREERSCONTACT US Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences". Oct 29, 2020. Laurus Labs Press Release Board Meeting Oct 29 2020. Oct 29, 2020. Q2 H1 FY21 Press Release Oct 29 2020. Jul 30, 2020. Press Release - Strong Revenue growth of 77% and PAT growth of 1047%. ABOUT US | LAURUS LABS Home / About us As a leading research-driven pharmaceutical company, Laurus Labs aims to improve the quality of life for millions around the world. We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality andaffordability.
CONTACT US | LAURUS LABS 400 Connell Drive, Suite 5200 Berkeley Heights, NJ 07922. Tel: 313-580-0229. Email: tversosky@lauruslabs.com. Laurus Generics GmbH Inc. Van-der-Smissen-Strasse 1, 22767 Hamburg, Germany. Tel: +49 40 3808 47 64.
INVESTORS | LAURUS LABS For redressal of any grievances, the shareholders/investors may contact the following: The Company Secretary. Laurus Labs Limited. 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 500 034, India. Phone: +91 40 39804333. E-mail: Secretarial@Lauruslabs.com. FACILITIES | LAURUS LABS Plot No. 21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India. API manufacturing facility includes capacity for ingredients, synthesis and contract manufacturing. Spread across 34 acres, and 1000+ employees; Isolated SYNTHESIS | LAURUS LABS We offer cutting-edge synthesis services trusted by leading research labs and companies worldwide. Innovative, robust and scalable chemistry is the core strength of Laurus. We support drug development and manufacturing programs for global pharmaceutical and biotech companies at all stages from pre-clinical stage to commercialization. CAREERS | LAURUS LABS CAREERS We are a team of thinkers and doers who share a passion to make a positive difference. Ask anyone of their impression of Laurus Labs. They will tell you that it feels like a close-knit family and that captures the essence of the Laurus experience.INGREDIENTS
We developed technologies for several key ingredients including carotenoids (Betacarotene, Astaxanthin), Huperzine A and novel nutraceutical co-crystals of Pterostilbene, Caffeine and Curcumin with enhanced bioavailability and controlled absorption properties. Laurus also manufactures safe and effective natural ingredients for weightmanagement
FINANCIALS | LAURUS LABS FY 2017-18. Sriam Labs Pvt Ltd-Audited Financials. Laurus Synthesis Inc Audited Financials INR. Laurus Synthesis Inc Audited Financials USD. Laurus Holdings Ltd Audited Financials INR. Laurus Holdings Ltd Audited Financials GBP. Laurus Generics Inc-Audited Financials. Laurus Generics GmbH-Audited Financials. FY 2016-17.LAURUS LABS
Key Indices' highlighting the progress of Laurus 55+ 290+ R&D Labs Manufacturing Facilities (India, USA) revenue in FY17 8 (8 API (incl.Pilot); 1 FDF)
LAURUS LABSABOUT USBUSINESS UNITSINVESTORSMEDIACAREERSCONTACT US Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences". Oct 29, 2020. Laurus Labs Press Release Board Meeting Oct 29 2020. Oct 29, 2020. Q2 H1 FY21 Press Release Oct 29 2020. Jul 30, 2020. Press Release - Strong Revenue growth of 77% and PAT growth of 1047%. ABOUT US | LAURUS LABS Home / About us As a leading research-driven pharmaceutical company, Laurus Labs aims to improve the quality of life for millions around the world. We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality andaffordability.
CONTACT US | LAURUS LABS 400 Connell Drive, Suite 5200 Berkeley Heights, NJ 07922. Tel: 313-580-0229. Email: tversosky@lauruslabs.com. Laurus Generics GmbH Inc. Van-der-Smissen-Strasse 1, 22767 Hamburg, Germany. Tel: +49 40 3808 47 64.
INVESTORS | LAURUS LABS For redressal of any grievances, the shareholders/investors may contact the following: The Company Secretary. Laurus Labs Limited. 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 500 034, India. Phone: +91 40 39804333. E-mail: Secretarial@Lauruslabs.com. FACILITIES | LAURUS LABS Plot No. 21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India. API manufacturing facility includes capacity for ingredients, synthesis and contract manufacturing. Spread across 34 acres, and 1000+ employees; Isolated SYNTHESIS | LAURUS LABS We offer cutting-edge synthesis services trusted by leading research labs and companies worldwide. Innovative, robust and scalable chemistry is the core strength of Laurus. We support drug development and manufacturing programs for global pharmaceutical and biotech companies at all stages from pre-clinical stage to commercialization. CAREERS | LAURUS LABS CAREERS We are a team of thinkers and doers who share a passion to make a positive difference. Ask anyone of their impression of Laurus Labs. They will tell you that it feels like a close-knit family and that captures the essence of the Laurus experience.INGREDIENTS
We developed technologies for several key ingredients including carotenoids (Betacarotene, Astaxanthin), Huperzine A and novel nutraceutical co-crystals of Pterostilbene, Caffeine and Curcumin with enhanced bioavailability and controlled absorption properties. Laurus also manufactures safe and effective natural ingredients for weightmanagement
FINANCIALS | LAURUS LABS FY 2017-18. Sriam Labs Pvt Ltd-Audited Financials. Laurus Synthesis Inc Audited Financials INR. Laurus Synthesis Inc Audited Financials USD. Laurus Holdings Ltd Audited Financials INR. Laurus Holdings Ltd Audited Financials GBP. Laurus Generics Inc-Audited Financials. Laurus Generics GmbH-Audited Financials. FY 2016-17.LAURUS LABS
Key Indices' highlighting the progress of Laurus 55+ 290+ R&D Labs Manufacturing Facilities (India, USA) revenue in FY17 8 (8 API (incl.Pilot); 1 FDF)
WHAT WE DO | LAURUS LABS Home / What we do At Laurus Labs, we are driven by an ambitious vision to secure market leadership in our core focus areas. Laurus Labs aspires to become a most-admired pharmaceutical company with a clear focus on four growing areas: APIs, FDFs, ingredients and synthesis.INGREDIENTS
We developed technologies for several key ingredients including carotenoids (Betacarotene, Astaxanthin), Huperzine A and novel nutraceutical co-crystals of Pterostilbene, Caffeine and Curcumin with enhanced bioavailability and controlled absorption properties. Laurus also manufactures safe and effective natural ingredients for weightmanagement
MEDIA | LAURUS LABS
Media Coverage. 29 Apr 2021. Laurus Labs Financial Results Q4 FY 2021 Press Release. 04 Mar 2021. Laurus labs promoters, Dr.Satyanarayana chava, founder and ceo & Mrs. Nagarani chava, promoter, are set to release the pledge of shares of the company. 10 Feb 2021. Laurus Labs wins coveted Golden Peacock Award for Excellence in CorporateGovernance.
RESEARCH & DEVELOPMENT As a science-led pharmaceutical company, we invest in cutting-edge research to develop new cures for challenging diseases. We are focused on undertaking dedicated R&D in areas with significant demand. Our research team of over 750 scientists constitutes a quarter of our total workforce. Our systematic approach to the selection of moleculesSHAREHOLDING
Shares. Unclaimed dividend details of 2019-20 Interim Dividend (Sep 30, 2020) Unclaimed Dividend Details of 2018-19 (October 31, 2019) Unclaimed Dividend Details of 2017-18 (October 31, 2018) Unclaimed Dividend Details of 2016-17 (November 28, 2017) Shareholding STRENGTHS & STRATEGY Established track record of delivering growth. From our incorporation in 2005, we have delivered consistent growth both in terms of financial and operational metrics. Our total revenues have grown at a CAGR of 41.1% from FY 2012 to FY 2016 and our restated profit has grown at a CAGR of 57.5% between FY 2012 and FY 2016.GENERICS FDF
Laurus has dedicated formulation research labs, laboratory-scale clinical supply facilities, and analytical research labs capable of developing different types of dosage forms. We create tangible value for customers by leveraging our cost-effective processes and large capacities in the API business. Our FDF business builds on ourstrengths in
GENERICS API
Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed a wide range of in-house APIs and intermediates. We focus on chemistry where we can make a difference and combine innovation with efficiency to develop cost-effective and hence affordable processes. We regularly invest inbuilding capacities
DISCLOSURES
04 Mar 2021. Laurus labs promoters, Dr.Satyanarayana chava, founder and ceo & Mrs. Nagarani chava, promoter, are set to release the pledge of shares of the company. 20 Feb 2021. Laurus Labs wins coveted Golden Peacock Award for Excellence in Corporate Governance. CORPORATE GOVERNANCE Laurus Labs is committed to conducting its business with the highest standards of integrity, with the Board providing indispensable leadership. The corporate governance framework at Laurus Labs is based on an effective independent Board, separation of the Board’s supervisory role from the executive management team, constitution ofthe Board
LAURUS LABSABOUT USBUSINESS UNITSINVESTORSMEDIACAREERSCONTACT US Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences". Oct 29, 2020. Laurus Labs Press Release Board Meeting Oct 29 2020. Oct 29, 2020. Q2 H1 FY21 Press Release Oct 29 2020. Jul 30, 2020. Press Release - Strong Revenue growth of 77% and PAT growth of 1047%. ABOUT US | LAURUS LABS Home / About us As a leading research-driven pharmaceutical company, Laurus Labs aims to improve the quality of life for millions around the world. We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality andaffordability.
CONTACT US | LAURUS LABS 400 Connell Drive, Suite 5200 Berkeley Heights, NJ 07922. Tel: 313-580-0229. Email: tversosky@lauruslabs.com. Laurus Generics GmbH Inc. Van-der-Smissen-Strasse 1, 22767 Hamburg, Germany. Tel: +49 40 3808 47 64.
WHAT WE DO | LAURUS LABS Home / What we do At Laurus Labs, we are driven by an ambitious vision to secure market leadership in our core focus areas. Laurus Labs aspires to become a most-admired pharmaceutical company with a clear focus on four growing areas: APIs, FDFs, ingredients and synthesis. INVESTORS | LAURUS LABS For redressal of any grievances, the shareholders/investors may contact the following: The Company Secretary. Laurus Labs Limited. 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 500 034, India. Phone: +91 40 39804333. E-mail: Secretarial@Lauruslabs.com. FACILITIES | LAURUS LABS Plot No. 21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India. API manufacturing facility includes capacity for ingredients, synthesis and contract manufacturing. Spread across 34 acres, and 1000+ employees; Isolated CAREERS | LAURUS LABS CAREERS We are a team of thinkers and doers who share a passion to make a positive difference. Ask anyone of their impression of Laurus Labs. They will tell you that it feels like a close-knit family and that captures the essence of the Laurus experience.INGREDIENTS
We developed technologies for several key ingredients including carotenoids (Betacarotene, Astaxanthin), Huperzine A and novel nutraceutical co-crystals of Pterostilbene, Caffeine and Curcumin with enhanced bioavailability and controlled absorption properties. Laurus also manufactures safe and effective natural ingredients for weightmanagement
FINANCIALS | LAURUS LABS FY 2017-18. Sriam Labs Pvt Ltd-Audited Financials. Laurus Synthesis Inc Audited Financials INR. Laurus Synthesis Inc Audited Financials USD. Laurus Holdings Ltd Audited Financials INR. Laurus Holdings Ltd Audited Financials GBP. Laurus Generics Inc-Audited Financials. Laurus Generics GmbH-Audited Financials. FY 2016-17.LAURUS LABS
Key Indices' highlighting the progress of Laurus 55+ 290+ R&D Labs Manufacturing Facilities (India, USA) revenue in FY17 8 (8 API (incl.Pilot); 1 FDF)
LAURUS LABSABOUT USBUSINESS UNITSINVESTORSMEDIACAREERSCONTACT US Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences". Oct 29, 2020. Laurus Labs Press Release Board Meeting Oct 29 2020. Oct 29, 2020. Q2 H1 FY21 Press Release Oct 29 2020. Jul 30, 2020. Press Release - Strong Revenue growth of 77% and PAT growth of 1047%. ABOUT US | LAURUS LABS Home / About us As a leading research-driven pharmaceutical company, Laurus Labs aims to improve the quality of life for millions around the world. We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality andaffordability.
CONTACT US | LAURUS LABS 400 Connell Drive, Suite 5200 Berkeley Heights, NJ 07922. Tel: 313-580-0229. Email: tversosky@lauruslabs.com. Laurus Generics GmbH Inc. Van-der-Smissen-Strasse 1, 22767 Hamburg, Germany. Tel: +49 40 3808 47 64.
WHAT WE DO | LAURUS LABS Home / What we do At Laurus Labs, we are driven by an ambitious vision to secure market leadership in our core focus areas. Laurus Labs aspires to become a most-admired pharmaceutical company with a clear focus on four growing areas: APIs, FDFs, ingredients and synthesis. INVESTORS | LAURUS LABS For redressal of any grievances, the shareholders/investors may contact the following: The Company Secretary. Laurus Labs Limited. 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 500 034, India. Phone: +91 40 39804333. E-mail: Secretarial@Lauruslabs.com. FACILITIES | LAURUS LABS Plot No. 21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India. API manufacturing facility includes capacity for ingredients, synthesis and contract manufacturing. Spread across 34 acres, and 1000+ employees; Isolated CAREERS | LAURUS LABS CAREERS We are a team of thinkers and doers who share a passion to make a positive difference. Ask anyone of their impression of Laurus Labs. They will tell you that it feels like a close-knit family and that captures the essence of the Laurus experience.INGREDIENTS
We developed technologies for several key ingredients including carotenoids (Betacarotene, Astaxanthin), Huperzine A and novel nutraceutical co-crystals of Pterostilbene, Caffeine and Curcumin with enhanced bioavailability and controlled absorption properties. Laurus also manufactures safe and effective natural ingredients for weightmanagement
FINANCIALS | LAURUS LABS FY 2017-18. Sriam Labs Pvt Ltd-Audited Financials. Laurus Synthesis Inc Audited Financials INR. Laurus Synthesis Inc Audited Financials USD. Laurus Holdings Ltd Audited Financials INR. Laurus Holdings Ltd Audited Financials GBP. Laurus Generics Inc-Audited Financials. Laurus Generics GmbH-Audited Financials. FY 2016-17.LAURUS LABS
Key Indices' highlighting the progress of Laurus 55+ 290+ R&D Labs Manufacturing Facilities (India, USA) revenue in FY17 8 (8 API (incl.Pilot); 1 FDF)
SYNTHESIS | LAURUS LABS We offer cutting-edge synthesis services trusted by leading research labs and companies worldwide. Innovative, robust and scalable chemistry is the core strength of Laurus. We support drug development and manufacturing programs for global pharmaceutical and biotech companies at all stages from pre-clinical stage to commercialization.INGREDIENTS
We developed technologies for several key ingredients including carotenoids (Betacarotene, Astaxanthin), Huperzine A and novel nutraceutical co-crystals of Pterostilbene, Caffeine and Curcumin with enhanced bioavailability and controlled absorption properties. Laurus also manufactures safe and effective natural ingredients for weightmanagement
RESEARCH & DEVELOPMENT As a science-led pharmaceutical company, we invest in cutting-edge research to develop new cures for challenging diseases. We are focused on undertaking dedicated R&D in areas with significant demand. Our research team of over 750 scientists constitutes a quarter of our total workforce. Our systematic approach to the selection of moleculesSHAREHOLDING
Shares. Unclaimed dividend details of 2019-20 Interim Dividend (Sep 30, 2020) Unclaimed Dividend Details of 2018-19 (October 31, 2019) Unclaimed Dividend Details of 2017-18 (October 31, 2018) Unclaimed Dividend Details of 2016-17 (November 28, 2017) Shareholding LEADERSHIP | LAURUS LABS Laurus Labs is led by an experienced team of executives who bring a deep understanding of the global pharmaceutical industry. They have proven abilities in delivering industry-leading growth and operational performance. Our executive team articulates a clear strategy for Laurus and helps us institutionalise world-class processes across thecompany.
STRENGTHS & STRATEGY Established track record of delivering growth. From our incorporation in 2005, we have delivered consistent growth both in terms of financial and operational metrics. Our total revenues have grown at a CAGR of 41.1% from FY 2012 to FY 2016 and our restated profit has grown at a CAGR of 57.5% between FY 2012 and FY 2016.GENERICS API
Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed a wide range of in-house APIs and intermediates. We focus on chemistry where we can make a difference and combine innovation with efficiency to develop cost-effective and hence affordable processes. We regularly invest inbuilding capacities
GENERICS FDF
Laurus has dedicated formulation research labs, laboratory-scale clinical supply facilities, and analytical research labs capable of developing different types of dosage forms. We create tangible value for customers by leveraging our cost-effective processes and large capacities in the API business. Our FDF business builds on ourstrengths in
CORPORATE GOVERNANCE Laurus Labs is committed to conducting its business with the highest standards of integrity, with the Board providing indispensable leadership. The corporate governance framework at Laurus Labs is based on an effective independent Board, separation of the Board’s supervisory role from the executive management team, constitution ofthe Board
CORPORATE SUSTAINABILITY ABOUT US / Corporate Sustainability As a responsible corporate citizen, we will conduct our business with complete respect for the environment and community. We have adopted a Corporate Social Responsibility (“CSR”) policy in compliance with the requirements of the Companies Act, 2013 and the Companies (Corporate Social Responsibility) Rules, 2014 notified by Central Government. LAURUS LABSABOUT USBUSINESS UNITSINVESTORSMEDIACAREERSCONTACT US Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences". Oct 29, 2020. Laurus Labs Press Release Board Meeting Oct 29 2020. Oct 29, 2020. Q2 H1 FY21 Press Release Oct 29 2020. Jul 30, 2020. Press Release - Strong Revenue growth of 77% and PAT growth of 1047%. ABOUT US | LAURUS LABS Home / About us As a leading research-driven pharmaceutical company, Laurus Labs aims to improve the quality of life for millions around the world. We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality andaffordability.
CONTACT US | LAURUS LABS 400 Connell Drive, Suite 5200 Berkeley Heights, NJ 07922. Tel: 313-580-0229. Email: tversosky@lauruslabs.com. Laurus Generics GmbH Inc. Van-der-Smissen-Strasse 1, 22767 Hamburg, Germany. Tel: +49 40 3808 47 64.
WHAT WE DO | LAURUS LABS Home / What we do At Laurus Labs, we are driven by an ambitious vision to secure market leadership in our core focus areas. Laurus Labs aspires to become a most-admired pharmaceutical company with a clear focus on four growing areas: APIs, FDFs, ingredients and synthesis. INVESTORS | LAURUS LABS For redressal of any grievances, the shareholders/investors may contact the following: The Company Secretary. Laurus Labs Limited. 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 500 034, India. Phone: +91 40 39804333. E-mail: Secretarial@Lauruslabs.com. FACILITIES | LAURUS LABS Plot No. 21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India. API manufacturing facility includes capacity for ingredients, synthesis and contract manufacturing. Spread across 34 acres, and 1000+ employees; Isolated SYNTHESIS | LAURUS LABS We offer cutting-edge synthesis services trusted by leading research labs and companies worldwide. Innovative, robust and scalable chemistry is the core strength of Laurus. We support drug development and manufacturing programs for global pharmaceutical and biotech companies at all stages from pre-clinical stage to commercialization. CAREERS | LAURUS LABS CAREERS We are a team of thinkers and doers who share a passion to make a positive difference. Ask anyone of their impression of Laurus Labs. They will tell you that it feels like a close-knit family and that captures the essence of the Laurus experience. FINANCIALS | LAURUS LABS FY 2017-18. Sriam Labs Pvt Ltd-Audited Financials. Laurus Synthesis Inc Audited Financials INR. Laurus Synthesis Inc Audited Financials USD. Laurus Holdings Ltd Audited Financials INR. Laurus Holdings Ltd Audited Financials GBP. Laurus Generics Inc-Audited Financials. Laurus Generics GmbH-Audited Financials. FY 2016-17.SHAREHOLDING
Shares. Unclaimed dividend details of 2019-20 Interim Dividend (Sep 30, 2020) Unclaimed Dividend Details of 2018-19 (October 31, 2019) Unclaimed Dividend Details of 2017-18 (October 31, 2018) Unclaimed Dividend Details of 2016-17 (November 28, 2017) Shareholding. FINANCIAL RESULTS FY2020-21. LAURUS LABSABOUT USBUSINESS UNITSINVESTORSMEDIACAREERSCONTACT US Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences". Oct 29, 2020. Laurus Labs Press Release Board Meeting Oct 29 2020. Oct 29, 2020. Q2 H1 FY21 Press Release Oct 29 2020. Jul 30, 2020. Press Release - Strong Revenue growth of 77% and PAT growth of 1047%. ABOUT US | LAURUS LABS Home / About us As a leading research-driven pharmaceutical company, Laurus Labs aims to improve the quality of life for millions around the world. We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality andaffordability.
CONTACT US | LAURUS LABS 400 Connell Drive, Suite 5200 Berkeley Heights, NJ 07922. Tel: 313-580-0229. Email: tversosky@lauruslabs.com. Laurus Generics GmbH Inc. Van-der-Smissen-Strasse 1, 22767 Hamburg, Germany. Tel: +49 40 3808 47 64.
WHAT WE DO | LAURUS LABS Home / What we do At Laurus Labs, we are driven by an ambitious vision to secure market leadership in our core focus areas. Laurus Labs aspires to become a most-admired pharmaceutical company with a clear focus on four growing areas: APIs, FDFs, ingredients and synthesis. INVESTORS | LAURUS LABS For redressal of any grievances, the shareholders/investors may contact the following: The Company Secretary. Laurus Labs Limited. 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 500 034, India. Phone: +91 40 39804333. E-mail: Secretarial@Lauruslabs.com. FACILITIES | LAURUS LABS Plot No. 21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India. API manufacturing facility includes capacity for ingredients, synthesis and contract manufacturing. Spread across 34 acres, and 1000+ employees; Isolated SYNTHESIS | LAURUS LABS We offer cutting-edge synthesis services trusted by leading research labs and companies worldwide. Innovative, robust and scalable chemistry is the core strength of Laurus. We support drug development and manufacturing programs for global pharmaceutical and biotech companies at all stages from pre-clinical stage to commercialization. CAREERS | LAURUS LABS CAREERS We are a team of thinkers and doers who share a passion to make a positive difference. Ask anyone of their impression of Laurus Labs. They will tell you that it feels like a close-knit family and that captures the essence of the Laurus experience. FINANCIALS | LAURUS LABS FY 2017-18. Sriam Labs Pvt Ltd-Audited Financials. Laurus Synthesis Inc Audited Financials INR. Laurus Synthesis Inc Audited Financials USD. Laurus Holdings Ltd Audited Financials INR. Laurus Holdings Ltd Audited Financials GBP. Laurus Generics Inc-Audited Financials. Laurus Generics GmbH-Audited Financials. FY 2016-17.SHAREHOLDING
Shares. Unclaimed dividend details of 2019-20 Interim Dividend (Sep 30, 2020) Unclaimed Dividend Details of 2018-19 (October 31, 2019) Unclaimed Dividend Details of 2017-18 (October 31, 2018) Unclaimed Dividend Details of 2016-17 (November 28, 2017) Shareholding. FINANCIAL RESULTS FY2020-21. SYNTHESIS | LAURUS LABS We offer cutting-edge synthesis services trusted by leading research labs and companies worldwide. Innovative, robust and scalable chemistry is the core strength of Laurus. We support drug development and manufacturing programs for global pharmaceutical and biotech companies at all stages from pre-clinical stage to commercialization.INGREDIENTS
We developed technologies for several key ingredients including carotenoids (Betacarotene, Astaxanthin), Huperzine A and novel nutraceutical co-crystals of Pterostilbene, Caffeine and Curcumin with enhanced bioavailability and controlled absorption properties. Laurus also manufactures safe and effective natural ingredients for weightmanagement
MEDIA | LAURUS LABS
Media Coverage. 29 Apr 2021. Laurus Labs Financial Results Q4 FY 2021 Press Release. 04 Mar 2021. Laurus labs promoters, Dr.Satyanarayana chava, founder and ceo & Mrs. Nagarani chava, promoter, are set to release the pledge of shares of the company. 10 Feb 2021. Laurus Labs wins coveted Golden Peacock Award for Excellence in CorporateGovernance.
SHAREHOLDING
Shares. Unclaimed dividend details of 2019-20 Interim Dividend (Sep 30, 2020) Unclaimed Dividend Details of 2018-19 (October 31, 2019) Unclaimed Dividend Details of 2017-18 (October 31, 2018) Unclaimed Dividend Details of 2016-17 (November 28, 2017) Shareholding RESEARCH & DEVELOPMENT As a science-led pharmaceutical company, we invest in cutting-edge research to develop new cures for challenging diseases. We are focused on undertaking dedicated R&D in areas with significant demand. Our research team of over 750 scientists constitutes a quarter of our total workforce. Our systematic approach to the selection of molecules STRENGTHS & STRATEGY Established track record of delivering growth. From our incorporation in 2005, we have delivered consistent growth both in terms of financial and operational metrics. Our total revenues have grown at a CAGR of 41.1% from FY 2012 to FY 2016 and our restated profit has grown at a CAGR of 57.5% between FY 2012 and FY 2016.GENERICS API
Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed a wide range of in-house APIs and intermediates. We focus on chemistry where we can make a difference and combine innovation with efficiency to develop cost-effective and hence affordable processes. We regularly invest inbuilding capacities
GENERICS FDF
Laurus has dedicated formulation research labs, laboratory-scale clinical supply facilities, and analytical research labs capable of developing different types of dosage forms. We create tangible value for customers by leveraging our cost-effective processes and large capacities in the API business. Our FDF business builds on ourstrengths in
CORPORATE GOVERNANCE Laurus Labs is committed to conducting its business with the highest standards of integrity, with the Board providing indispensable leadership. The corporate governance framework at Laurus Labs is based on an effective independent Board, separation of the Board’s supervisory role from the executive management team, constitution ofthe Board
CORPORATE SUSTAINABILITY ABOUT US / Corporate Sustainability As a responsible corporate citizen, we will conduct our business with complete respect for the environment and community. We have adopted a Corporate Social Responsibility (“CSR”) policy in compliance with the requirements of the Companies Act, 2013 and the Companies (Corporate Social Responsibility) Rules, 2014 notified by Central Government. LAURUS LABSABOUT USBUSINESS UNITSINVESTORSMEDIACAREERSCONTACT US Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences". Oct 29, 2020. Laurus Labs Press Release Board Meeting Oct 29 2020. Oct 29, 2020. Q2 H1 FY21 Press Release Oct 29 2020. Jul 30, 2020. Press Release - Strong Revenue growth of 77% and PAT growth of 1047%. ABOUT US | LAURUS LABS Home / About us As a leading research-driven pharmaceutical company, Laurus Labs aims to improve the quality of life for millions around the world. We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality andaffordability.
CONTACT US | LAURUS LABS 400 Connell Drive, Suite 5200 Berkeley Heights, NJ 07922. Tel: 313-580-0229. Email: tversosky@lauruslabs.com. Laurus Generics GmbH Inc. Van-der-Smissen-Strasse 1, 22767 Hamburg, Germany. Tel: +49 40 3808 47 64.
WHAT WE DO | LAURUS LABS Home / What we do At Laurus Labs, we are driven by an ambitious vision to secure market leadership in our core focus areas. Laurus Labs aspires to become a most-admired pharmaceutical company with a clear focus on four growing areas: APIs, FDFs, ingredients and synthesis. INVESTORS | LAURUS LABS For redressal of any grievances, the shareholders/investors may contact the following: The Company Secretary. Laurus Labs Limited. 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 500 034, India. Phone: +91 40 39804333. E-mail: Secretarial@Lauruslabs.com. FACILITIES | LAURUS LABS Plot No. 21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India. API manufacturing facility includes capacity for ingredients, synthesis and contract manufacturing. Spread across 34 acres, and 1000+ employees; Isolated SYNTHESIS | LAURUS LABS We offer cutting-edge synthesis services trusted by leading research labs and companies worldwide. Innovative, robust and scalable chemistry is the core strength of Laurus. We support drug development and manufacturing programs for global pharmaceutical and biotech companies at all stages from pre-clinical stage to commercialization.SHAREHOLDING
Shares. Unclaimed dividend details of 2019-20 Interim Dividend (Sep 30, 2020) Unclaimed Dividend Details of 2018-19 (October 31, 2019) Unclaimed Dividend Details of 2017-18 (October 31, 2018) Unclaimed Dividend Details of 2016-17 (November 28, 2017) Shareholding. FINANCIAL RESULTS FY2020-21. CAREERS | LAURUS LABS CAREERS We are a team of thinkers and doers who share a passion to make a positive difference. Ask anyone of their impression of Laurus Labs. They will tell you that it feels like a close-knit family and that captures the essence of the Laurus experience. FINANCIALS | LAURUS LABS FY 2017-18. Sriam Labs Pvt Ltd-Audited Financials. Laurus Synthesis Inc Audited Financials INR. Laurus Synthesis Inc Audited Financials USD. Laurus Holdings Ltd Audited Financials INR. Laurus Holdings Ltd Audited Financials GBP. Laurus Generics Inc-Audited Financials. Laurus Generics GmbH-Audited Financials. FY 2016-17. LAURUS LABSABOUT USBUSINESS UNITSINVESTORSMEDIACAREERSCONTACT US Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences". Oct 29, 2020. Laurus Labs Press Release Board Meeting Oct 29 2020. Oct 29, 2020. Q2 H1 FY21 Press Release Oct 29 2020. Jul 30, 2020. Press Release - Strong Revenue growth of 77% and PAT growth of 1047%. ABOUT US | LAURUS LABS Home / About us As a leading research-driven pharmaceutical company, Laurus Labs aims to improve the quality of life for millions around the world. We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality andaffordability.
CONTACT US | LAURUS LABS 400 Connell Drive, Suite 5200 Berkeley Heights, NJ 07922. Tel: 313-580-0229. Email: tversosky@lauruslabs.com. Laurus Generics GmbH Inc. Van-der-Smissen-Strasse 1, 22767 Hamburg, Germany. Tel: +49 40 3808 47 64.
WHAT WE DO | LAURUS LABS Home / What we do At Laurus Labs, we are driven by an ambitious vision to secure market leadership in our core focus areas. Laurus Labs aspires to become a most-admired pharmaceutical company with a clear focus on four growing areas: APIs, FDFs, ingredients and synthesis. INVESTORS | LAURUS LABS For redressal of any grievances, the shareholders/investors may contact the following: The Company Secretary. Laurus Labs Limited. 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 500 034, India. Phone: +91 40 39804333. E-mail: Secretarial@Lauruslabs.com. FACILITIES | LAURUS LABS Plot No. 21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India. API manufacturing facility includes capacity for ingredients, synthesis and contract manufacturing. Spread across 34 acres, and 1000+ employees; Isolated SYNTHESIS | LAURUS LABS We offer cutting-edge synthesis services trusted by leading research labs and companies worldwide. Innovative, robust and scalable chemistry is the core strength of Laurus. We support drug development and manufacturing programs for global pharmaceutical and biotech companies at all stages from pre-clinical stage to commercialization.SHAREHOLDING
Shares. Unclaimed dividend details of 2019-20 Interim Dividend (Sep 30, 2020) Unclaimed Dividend Details of 2018-19 (October 31, 2019) Unclaimed Dividend Details of 2017-18 (October 31, 2018) Unclaimed Dividend Details of 2016-17 (November 28, 2017) Shareholding. FINANCIAL RESULTS FY2020-21. CAREERS | LAURUS LABS CAREERS We are a team of thinkers and doers who share a passion to make a positive difference. Ask anyone of their impression of Laurus Labs. They will tell you that it feels like a close-knit family and that captures the essence of the Laurus experience. FINANCIALS | LAURUS LABS FY 2017-18. Sriam Labs Pvt Ltd-Audited Financials. Laurus Synthesis Inc Audited Financials INR. Laurus Synthesis Inc Audited Financials USD. Laurus Holdings Ltd Audited Financials INR. Laurus Holdings Ltd Audited Financials GBP. Laurus Generics Inc-Audited Financials. Laurus Generics GmbH-Audited Financials. FY 2016-17. SYNTHESIS | LAURUS LABS We offer cutting-edge synthesis services trusted by leading research labs and companies worldwide. Innovative, robust and scalable chemistry is the core strength of Laurus. We support drug development and manufacturing programs for global pharmaceutical and biotech companies at all stages from pre-clinical stage to commercialization.INGREDIENTS
We developed technologies for several key ingredients including carotenoids (Betacarotene, Astaxanthin), Huperzine A and novel nutraceutical co-crystals of Pterostilbene, Caffeine and Curcumin with enhanced bioavailability and controlled absorption properties. Laurus also manufactures safe and effective natural ingredients for weightmanagement
MEDIA | LAURUS LABS
Media Coverage. 29 Apr 2021. Laurus Labs Financial Results Q4 FY 2021 Press Release. 04 Mar 2021. Laurus labs promoters, Dr.Satyanarayana chava, founder and ceo & Mrs. Nagarani chava, promoter, are set to release the pledge of shares of the company. 10 Feb 2021. Laurus Labs wins coveted Golden Peacock Award for Excellence in CorporateGovernance.
SHAREHOLDING
Shares. Unclaimed dividend details of 2019-20 Interim Dividend (Sep 30, 2020) Unclaimed Dividend Details of 2018-19 (October 31, 2019) Unclaimed Dividend Details of 2017-18 (October 31, 2018) Unclaimed Dividend Details of 2016-17 (November 28, 2017) Shareholding RESEARCH & DEVELOPMENT As a science-led pharmaceutical company, we invest in cutting-edge research to develop new cures for challenging diseases. We are focused on undertaking dedicated R&D in areas with significant demand. Our research team of over 750 scientists constitutes a quarter of our total workforce. Our systematic approach to the selection of molecules STRENGTHS & STRATEGY Established track record of delivering growth. From our incorporation in 2005, we have delivered consistent growth both in terms of financial and operational metrics. Our total revenues have grown at a CAGR of 41.1% from FY 2012 to FY 2016 and our restated profit has grown at a CAGR of 57.5% between FY 2012 and FY 2016.GENERICS API
Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed a wide range of in-house APIs and intermediates. We focus on chemistry where we can make a difference and combine innovation with efficiency to develop cost-effective and hence affordable processes. We regularly invest inbuilding capacities
GENERICS FDF
Laurus has dedicated formulation research labs, laboratory-scale clinical supply facilities, and analytical research labs capable of developing different types of dosage forms. We create tangible value for customers by leveraging our cost-effective processes and large capacities in the API business. Our FDF business builds on ourstrengths in
CORPORATE GOVERNANCE Laurus Labs is committed to conducting its business with the highest standards of integrity, with the Board providing indispensable leadership. The corporate governance framework at Laurus Labs is based on an effective independent Board, separation of the Board’s supervisory role from the executive management team, constitution ofthe Board
CORPORATE SUSTAINABILITY ABOUT US / Corporate Sustainability As a responsible corporate citizen, we will conduct our business with complete respect for the environment and community. We have adopted a Corporate Social Responsibility (“CSR”) policy in compliance with the requirements of the Companies Act, 2013 and the Companies (Corporate Social Responsibility) Rules, 2014 notified by Central Government. Skip to main content * ABOUT US
* About Laurus
* Research & Development* Leadership
* Strengths & Strategy * Corporate Sustainability* BUSINESS UNITS
* Generics API
* Generics FDF
* Ingredients
* Synthesis
* Facilities
* INVESTORS
* Home
* Financials
* Disclosures
* Shareholding
* Corporate Governance* MEDIA
* CAREERS
* CONTACT
* __
Laurus Generics GmbH Laurus Synthesis Laurus Generics Inc.__
X
* Home
* About Us
* About Laurus
* Research & Development* Leadership Team
* Strengths & Strategy * Corporate Sustainability* Business Units
* Generics API
* Generics FDF
* Ingredients
* Synthesis
* Facilities
* Investors
* Financials
* Disclosures
* Shares
* Corporate Governance* Media
* Careers
* Contact Us
* Laurus Generics GmbH* Laurus Synthesis
* Laurus Generics Inc. Q3 FY20 RESULTS ANNOUNCED REVENUES UP BY 38%; EBITDA AT 21%Read More
TWO TIMES IN A ROW
LAURUS LABS IS RECOGNISED AS A GREAT PLACE TO WORK FOR THE SECONDCONSECUTIVE TIME.
Read More
DOING WELL BY DOING GOOD WE ARE COMMITTED TO IMPROVING THE QUALITY OF LIFE THROUGH AFFORDABLEMEDICINES.
Read More
EXPANDING THE FRONTIERS OF SCIENCE OUR CUTTING-EDGE R&D CAPABILITIES ENABLE US TO FIND EFFECTIVE CURES FOR COMPLEX DISEASES.Read More
LAURUS ENTERS THE FDF MARKET TENOFOVIR (TDF) LAUNCH MARKS A KEY MILESTONE IN THE COMPANY'SGROWTH.
Read More
Q3 FY20 RESULTS ANNOUNCED REVENUES UP BY 38%; EBITDA AT 21%Read More
TWO TIMES IN A ROW
LAURUS LABS IS RECOGNISED AS A GREAT PLACE TO WORK FOR THE SECONDCONSECUTIVE TIME.
Read More
1
2
3
4
5
GENERIC API
Affordable and high-quality APIs manufactured with the highest GMPstandards.
Read more
GENERIC FDF
Innovative FDFs supported by world-class research capabilities.Read more
INGREDIENTS
Natural and nature-identical ingredients that improve overallwellness.
Read more
SYNTHESIS
Cutting-edge synthesis services trusted by leading companiesworldwide.
Read more
IMAGE OF THE LAURUS TREEWHO WE ARE?
We are a team of over 3000 talented and energetic individuals who strive to widen the frontiers of chemistry in order to help develop new cures, while building a profitable business. Team Laurus comprises of a healthy mix of pharmaceutical industry veterans, research scientists, and manufacturing and management professionals.Read more
PRESS RELEASES AND ANNOUNCEMENTS*
MAR 11, 2019
Laurus Labs receives two approvals from USFDA*
MAR 27, 2020
RISING PHARMACEUTICALS AND LAURUS LABS PARTNER TO SUPPORT THE UNIVERSITY OF MINNESOTA TO EXPLORE THE PROPHYLAXIS EFFECT OF HYDROXYCHLOROQUINE IN ESSENTIAL HEALTH CARE WORKERS*
MAR 26, 2020
LAURUS LABS DONATES HYDROXYCHLOROQUINE (HCQ) IP 200MG TABLETS & INR 50 LAKHS FUND TO FIGHT THE COVID-19 PANDEMIC IN TELANGANA AND ANDHRAPRADESH STATES
*
JAN 30, 2020
Laurus Labs Financial Results Q3 FY 2020 PressRelease*
NOV 21, 2019
Laurus Labs completes US FDA, pre-approval inspection (P AI), for an API manufactured at its units 1&3, Visakhapatnam*
NOV 08, 2019
Laurus Labs completed the USFDA Inspection of its FDF & API Integrated Facility, Unit 2, at Visakhapatnam*
OCT 30, 2019
Laurus Labs Financial Results Q2 FY 2020 Press Release*
SEP 18, 2019
Laurus Labs to acquire the Subsidiary Company of Aspen Pharmacare,South Africa
*
SEP 05, 2019
Laurus Labs receives an EIR from USFDA for its API Units 1 & 3 and also received an ERP approval for fixed dose combination TLE400 fromGlobal Fund
*
AUG 02, 2019
Q1 FY20 Results: Revenues up by 2 percent*
JULY 22, 2019
Laurus Labs' exclusive distribution partner Rising Pharmaceuticals, launches Pregabalin Capsules in US market*
JULY 12, 2019
Laurus Labs completed the US FDA inspection of Unit 4 at Visakhapatnam*
JUNE 14, 2019
USFDA inspection of API facilites Unit 1 & 3 at Visakhapatnam*
MAY 2, 2019
Laurus Labs revenues up by 11.5 percent in Q4*
MAR 26, 2019
Laurus Labs enters into strategic partnership agreement with theGlobal Fund
*
MAR 11, 2019
Laurus Labs receives two approvals from USFDA*
MAR 27, 2020
RISING PHARMACEUTICALS AND LAURUS LABS PARTNER TO SUPPORT THE UNIVERSITY OF MINNESOTA TO EXPLORE THE PROPHYLAXIS EFFECT OF HYDROXYCHLOROQUINE IN ESSENTIAL HEALTH CARE WORKERSNSE
342.15
18.45 __
BSE
342.15
18.70 __
LATEST TWEETS
ABOUT US
* About Laurus
* Research & Development* Leadership Team
* Strengths & Strategy * Corporate SustainabilityBUSINESS UNITS
* Generics API
* Generics FDF
* Ingredients
* Synthesis
* Facilities
INVESTORS
* Home
* Financials
* Disclosures
* Shares
* Corporate GovernanceCONNECT
* Media
* Careers
* Locations
* __
* __
* __
* __
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0